Novartis.com

By Rob Matheson | MIT News Office At yesterday’s launch event for The Engine — MIT’s new enterprise that aims to support local startups working on transformative technologies — MIT President L. Rafael Reif and other speakers discussed the numerous benefits...

ZURICH: Novartis is making progress in its bid to catch rivals developing drugs that harness the immune system to fight cancer, one of its top research scientists and latest recruit from Harvard University told Reuters in an interview. Peter Hammerman...

The Novartis Open Framework symposia are designed to stimulate discussions within the Boston community about the academia- industry interface, and how to optimize interactions between these environments in order to advance science and impact health....

Syros Pharmaceuticals has a long way to go before it knows whether its drug discovery work will pay off. But insiders and Wall Street investors have given the firm’s efforts a boost, helping it go public Wednesday evening with a $50 million IPO. Cambridge...

A few articles from this week's issue of C&EN: Cover: Bethany Halford on the science and delivery of naloxone. Don't miss the short article on the invention of naloxone in the United States. Lower carbon dioxide emissions in the US over the past...